PSA Rising - welcome!
powered by FreeFind
  • PSA Rising Home | blog latest entry| newswire | forums | books | about
  • Daily Entries
November 2006
S M T W T F S
« Oct    
 1234
567891011
12131415161718
19202122232425
2627282930  
  • TOPICS
    • Prostate Cancer
    • Provenge
    • Taxotere
    • Nutrition
    • Drug Info
    • Satraplatin
    • Activism
    • Jobs, Work, Disability
    • QOL
    • Fatigue
    • Legal issues
    • COX-2 inhibitors
    • Health Insurance
    • Imclone - Erbitux
    • Cancer
    • Vitamin D3
    • African American Cancer Disparities
    • Medical Ethics
    • Pollution
    • Thalidomide
    • Death & Dying
    • Avastin
    • ED
    • Treatment choice
    • Proton beam
    • Herbal Medicine
    • BPH
    • ADT: androgen deprivation tx
    • treatment side effects
    • Acapodene
    • Clinical trials
    • Clinical trial results
    • Vaccines
    • Brachytherapy
    • Vitamin-Mineral Supplements
    • Phenoxodiol
  • RSS feed
  • LINKS
    • Cancer Journals

      • Cancer Research (an AACR journal)
      • Clinical Cancer Research (an AACR Journal
    • Cancer Research

      • AACR
    • Environmental Health

      • Environmental Health Perspectives
    • Healthcare, insurance

      • Metastar
      • BenefitsCheckUpRx
      • Medicare & Prescription Help
      • Medicare
      • Eldercare locator
    • Home

      • PSA Rising
    • Medical Ethics

      • The Hutch "UNINFORMED CONSENT"
    • Nutrition

      • Consumer Lab Reviews
      • Dietary Supplements Info
      • Food Routes
      • nutrition.org
      • The New Farm
    • Prostate Cancer

      • Being a Patient (New York Times)
      • Free Multigraph
      • Fatigue
      • Angiogenesis section at Nature, 12/05
      • Terry Van Dyke's Lab
      • FDA > Trelstar
      • Xinlay - FDA review docs
      • My Cancer Blog - Daniel
      • WARRIOR GORD'S PCD
      • GRUPO DE APOYO PARA EL CANCER DE PROSTATA
      • Living with prostate cancer, a patient blog
      • Spanish Cancer Association
      • Prostate Action: Campaign is the Aim (UK)
      • Cycle for Life
      • San Jose Prostate Cancer Support Group
  • ARCHIVES
    • November 2006
    • October 2006
    • September 2006
    • July 2006
    • June 2006
    • May 2006
    • April 2006
    • March 2006
    • February 2006
    • January 2006
    • December 2005
    • November 2005
    • September 2005
  • Valid XHTML
  • XFN

Search just this blog

Join to add comments or your story

  • Register
  • Login

advertising

Eat to Beat Prostate Cancer Cookbook

Eat to Beat Prostate Cancer Cookbook Author: David Ricketts; buy New: $12.97

Intimacy with Impotence by Ralph Alterowitz

Intimacy with Impotence: The Couple's Guide to Better Sex after Prostate Disease by Ralph Alterowitz, Barbara Alterowitz. Price: $10.20

March 29, 2006

Hot Flashes — Neurontin (gabapentin) Comeback

category: Prostate Cancer, Cancer posted by admin @ 5:05 pm

New York Times health editor Jane Brody reported yesterday that the epilepsy drug Neurontin (gabapentin), prescribed off-label for her pain after knee replacement surgery, helped her menopausal hot flashes. Brody went back to her doctor and asked for more after her knee pain ceased.

Gabapentin was developed, Brody says, “to help avoid the addictive quality of drugs called GABA analogues (Valium, Ativan and Xanax) used for anxiety and seizure disorders. The modified drug proved nonaddictive.”

Since this drug is non-hormonal and works on the brain, I wonder if it relieves hot flashes in men taking androgen blockade for prostate cancer?
(full story…)

Comment (1)
• • •

March 26, 2006

Limitations of hormonal blockade for localized prostate cancer

category: Prostate Cancer posted by admin @ 4:09 pm

Wednesday, March 22, 2006

ANDY DWORKIN

Across the country, urologists increasingly give men with localized prostate cancers hormone-blocking treatments normally used on late-stage cancers.

Doctors hope that early use of the testosterone-fighting weapon might keep the cancer from spreading in the body.

But that is probably a pipe dream, Oregon Health & Science University researchers say.

In a group of 276 men who had this treatment at OHSU, almost one in 10 died from prostate cancer within five years.

“Ten percent dying at five years from any localized prostate cancer is not good,” said Dr. Tomasz Beer, director of OHSU’s Prostate Cancer Research Program. “What this suggests to me is that this treatment is not very effective.”
(full story…)

Comment (0)
• • •

March 23, 2006

Sometimes No Treatment is Best for Low-Risk Prostate Cancer

category: Prostate Cancer posted by admin @ 9:09 pm

When Houston restaurateur Tony Masraff was diagnosed with early-stage prostate cancer, his life was packed with dancing, running marathons, playing tennis, gardening, leading a successful business and spending time with his family.

But it wasn’t until his doctor at The University of Texas M. D. Anderson Cancer Center advised “watchful waiting” as an option to invasive surgery and radiation that he realized he could continue his active life - free of treatment side effects, but with the cancer.

Masraff is one of about 200 men diagnosed with low-risk prostate cancer at M. D. Anderson on active surveillance for their disease, having changes monitored through regular Prostate Specific Antigen (PSA) tests, biopsies and check-ups.
Full story

Comment (0)
• • •

March 22, 2006

Treating elderly men right after diagnosis is better than the current ‘watchful waiting’

category: Prostate Cancer posted by admin @ 8:35 pm

A New View on Prostate Cancer
Treating elderly men right after diagnosis is better than the current ‘watchful waiting’ approach, a study indicates.

By Thomas H. Maugh II, Times Staff Writer
Los Angeles Times
February 26 2006

It is better to treat prostate cancer in the elderly early on rather than to wait and watch for signs of progression, as is now commonly done, according to a new study that may change the care for many patients with the deadly disorder.

Surgery or radiation therapy in elderly men increases survival by at least 30%, raising median survival times from 10 years to more than 13 years, researchers reported Saturday at a prostate symposium in San Francisco.

The finding in a study of about 49,000 men “challenges long-held beliefs about prostate cancer treatment” by suggesting that treatment is better than so-called watchful waiting, said Dr. Paul Lange of the University of Washington, who did not participate in the study.

“It’s a wonderful paper that validates what many of us have believed for a long time,” said Dr. Mark Kawachi, director of the prostate cancer center at City of Hope National Medical Center in Duarte.

“Age, in and of itself, is not a definitive determinant of whether you should be excluded from treatment” for prostate cancer, he said.
(full story…)

Comment (0)
• • •

March 18, 2006

The looming shadow of prostate cancer

category: Prostate Cancer posted by admin @ 6:59 pm

FIGHTER: David Wright is making the most of the precious time he has left.

Within a month after David Wright, now 62, was diagnosed with prostate cancer he had been told by his doctor at the Western General Hospital in Scotland that the disease had spread so far into his bones that it was “incurable”.

Prostate cancer is now the cause of more cancer deaths in men in Scotland than any other form of the disease, claiming hundreds of lives each year.

Yet new figures released last week revealed that less than half - 48 per cent - of all men diagnosed with prostate cancer in Scotland began treatment within the two month standard set by the Scottish Executive last year.

While the message from David, 62, and prostate cancer groups is that more men should get checked, and therefore diagnosed, more quickly, the statistics raise fears that not enough is being done to treat them swiftly once the disease is spotted.

Sitting in his home in East Comiston, David says: “Prostate cancer is often described as a curable disease made incurable by late diagnosis.

“The most important message for men is not to ignore the signs - like problems with urination - and to get checked out.

“Not many men know this, but all men over 50 in Britain have the right to a simple blood test for prostate cancer called a PSA (prostate specific antigen).

“It is not 100 per cent reliable, and GPs don’t always want to do the test, but it picks up most cases which need further investigation.

“I certainly would not be in the position I’m in now if there had been routine testing.”

“Prostate cancer is a slow-growing cancer, so in a sense waiting times being missed is not as serious as it is for other cancers. Six months might go past from diagnosis and there could be little change in the cancer.

“But that is not to excuse hospitals. They must improve and I think they will.

“I think it’s the silence in the waiting which is more of a problem than the waiting itself. Men don’t know whether to ask their GP or the hospital for test results.”

Full story: Scotsman.com Living - Health - The looming shadow of prostate cancer

David Wright is chair of Edinburgh & Lothian Prostate Cancer Support Group.

Useful contacts: Edinburgh & Lothian Support Group, 0131 445 1960 or 01506 845981 or 0131 5528360 Garner; Prostate Cancer Charity Helpline, 0845 300 8383; Maggie’s Centre (Western General Hospital), 0131 537 3131. or email [email protected] or obtain details of support groups from the Scottish Association’s website, www.prostatescot.co.uk, or email, [email protected], or phone 01738 450415.

Comment (0)
• • •

Prostate Cancer Velocity Affected By Demographic and Lifestyle Factors

category: Prostate Cancer, Cancer posted by admin @ 6:44 pm

Speed of rise of prostate specific antigen that is measured in PSA blood test screening for prostate cancer may be affected by lifestyle and demographic factors, according to a study published in the January 15, 2006 issue of CANCER, a peer-reviewed journal of the American Cancer Society.

The study reveals that the rate of change in concentration of prostate specific antigen (PSA) over time - a calculation called PSA velocity - can be significantly affected by age, race, and diet, leading to falsely lower or elevated values and possible misinterpretation by doctors. Single determinations of PSA concentration, the most common use of the PSA screening test, were minimally but significantly affected by age and body mass index (BMI).
(full story…)

Comment (1)
• • •

March 17, 2006

Animal tests ‘false reassurance’

category: Prostate Cancer, Cancer posted by admin @ 10:40 pm

Animal tests on the kind of drug given to the six men ill in a London hospital may not be the best way of evaluating the effects in people, an expert warns.

The drug they took stimulates a protein only found in humans.

Dr David Glover, an expert in drug testing, said this meant animal tests of medicines of this sort might give falsely reassuring results.

He said it might be better to look at innovative ways of testing small amounts of such drugs on people.
Full story from BBC: BBC Animal tests ‘false reassurance’

Comment (0)
• • •

March 16, 2006

HELP STOP CUTS TO PROSTATE CANCER RESEARCH IN THE FY2007 BUDGET!

category: Prostate Cancer posted by admin @ 4:18 am

An urgent message from the National Prostate Cancer Coalition:

HELP STOP CUTS TO PROSTATE CANCER RESEARCH IN THE FY2007 BUDGET!

The President has proposed serious cuts to funding for cancer research
at the National Institute of Health and the Center for Disease Control
and Prevention. In order to stop these cuts from taking effect,
Senators Feinstein and Mikulski have offered an amendment to the FY07
Budget Resolution which would increase money to these federal programs
by offsetting corporate tax loopholes. Senators will be voting on this
amendment today or tomorrow.

How you can help:

Call your Senator today and ask them to vote for the
Feinstein-Mikulski Amendment to the FY07 Budget Resolution. Call the
Senate Switchboard at (202) 224-3121 and aske to be connected to your
Senator. If you don’t know who your Senators are, name the state
in which you live and you will be connected!

* Once connected to the office, ask to be connected to the
legislative assistant that handles health care.
* Share with them your personal story with cancer and share why
these programs are important to you, their constituent or simply
say:

- I am asking you to support the Feinstein-Mikulski and Specter-Harkin
Senate budget amendments for increased funding for health programs and
any other amendments that will give more money to Cancer research and
programs.

- Now is not the time to turn our back on Cancer research and
programs, when we’ve made so much progress in fighting this disease in
recent years.

Thank you very much for helping us in the fight against cancer.

National Prostate Cancer Coalition
1154 Fifteenth Street, NW
Washington, DC 20005

Tel: 202-463-9455
Fax: 202-463-9456

Comment (0)
• • •

March 15, 2006

Hot Peppers - any link with gastric cancer?

category: Prostate Cancer, Nutrition, Cancer posted by admin @ 6:12 am

photo: chili pepper,david allag

Capsaicin, the pungent alkaloid in jalapeños and other chile peppers that makes them hot, drives prostate cancer cells to kill themselves off, according to studies published in the March 15 issue of Cancer Research. See:
http://www.psa-rising.com/eatingwell/peppers_hot.htm

Some commentators reacted by warning that hot peppers may cause gastric cancer. Is this true? How strong is the association?

A study conducted at a Texas Veterans Administration hospital in 1988, published in the JAMA, injected about an ounce of jalapeno pepper directly into the stomachs of volunteers. Follow-up observation showed no damage to their stomach linings. But this did not amount to chronic exposure, and anti-cancer versus cancer-causing effects of capsaicin are still controversial. A couple of years ago Mexico National Institute of Public Health found higher rates of gastric cancer in people who ate the equivalent of 9-25 jalapeno peppers a day compared to people who no more than 3 a day. They found no evidence that bacterioa known to be associated with some types of stomach were causing this increased risk.
(full story…)

Comment (0)
• • •

March 14, 2006

Genistein Reverses Hypermethylation of Genes

category: Prostate Cancer, Nutrition, Cancer posted by admin @ 2:55 pm

Genistein, the major isoflavone from soy, has been shown to have cancer preventive activity, but the mechanisms are not clearly understood. Fang et al. demonstrate that treatment of human esophageal cancer cells with genistein (2–20 mmol/L) caused the reversal of hypermethylation and reactivation of retinoic acid receptor β, p16INK4a, and O6-methylguanine methyltransferase genes. Similar activity is also observed with human prostate cancer cells.

Greater extent of reactivation is observed when genistein is combined with low concentrations of trichostatin, sulforaphane, or 2’-deoxy-5-aza-cytidine. Reversal or prevention of the hypermethylation of key genes by genistein may contribute to its cancer prevention activity.

Source: October 1 Clinical Cancer Research Highlights | American Association for Cancer Research

Note: Sulforaphane is found in cruciferous veggies (brassica) like broccoli, broccoli sprouts, bok choy, kale, collards, cauliflower, cauliflower sprouts, arugula, kohlrabi, mustard, turnip, red radish and watercress, brussel sprouts and cabbage.

Comment (0)
• • •

Taxotere Plus Vaccine

category: Prostate Cancer, Taxotere, Drug Info posted by admin @ 2:30 pm

Docetaxel Plus Vaccine Extends Progression-Free Survival Rates In Prostate Cancer Patients

Docetaxel has activity against androgen-insensitive prostate cancer (AIPC). Arlen et al. designed a randomized Phase II study in AIPC patients to compare a prostate-specific antigen vector–based vaccine vs. vaccine plus docetaxel.

Patients in the vaccine alone arm were allowed to receive docetaxel at progression.

Median progression-free survival rates on docetaxel was 6.1 months after crossover from vaccine vs. 3.7 months with the same drug regimen and patient population in a previous trial. Larger prospective studies will be required to validate these findings.

This was the first study to show that patients in both arms (vaccine ± docetaxel) developed equal T-cell responses to prostate-specific antigen showing that docetaxel (with steroid) did not inhibit immune responses.
source: February 15 Clinical Cancer Research Highlights | American Association for Cancer Research

Comment (0)
• • •

March 13, 2006

Study: Electricity kills cancer cells

category: Prostate Cancer, Cancer posted by admin @ 9:37 pm

High-powered jolts of electricity, repeated many times, kill melanoma cells in mice. Scientists from Old Dominion University and Eastern Virginia Medical School say that using extremely short, high-voltage doses of electricity, they’ve never had a tumor that did not respond to the treatment.
Richard Nuccitelli, associate professor of electrical and computer engineering at Old Dominion, said the method might eventually turn into an effective cancer treatment.
physorg.com

Comment (0)
• • •

February 15, 2006

Avastin costs too much, may kill you too

category: Prostate Cancer, Cancer, Medical Ethics, Avastin posted by admin @ 2:17 am

Today’s New York Times is running a story by Alex Berenson in the business section about Genentech’s Avastin, A Cancer Drug Shows Promise, at a Price That Many Can’t Pay. “Doctors are excited about the prospect of Avastin, ” Berenson writes, “a drug already widely used for colon cancer, as a crucial new treatment for breast and lung cancer, too. But doctors are cringing at the price the maker, Genentech, plans to charge for it: about $100,000 a year.”
(full story…)

Comment (0)
• • •

February 14, 2006

Avastin Trial Deaths

category: Prostate Cancer, Cancer posted by admin @ 10:24 pm

Drug companies stop recruiting for cancer drug test after deaths
PAUL ELIAS
AP via Miami Herald reg Tue Feb 14 200
SAN FRANCISCO - Biotechnology giant Genentech Inc. and its majority stockholder Roche Holding AG said they temporarily halted recruiting volunteers for a large human test of the blockbuster cancer drug Avastin after more patients than expected died.

The deaths occurred among colon cancer patients taking Avastin with a chemotherapy regimen called XELOX. Since the test was started in December 2004, seven patients taking that combination died, four of them suddenly, Roche said in a press release Monday.

“An occurrence of sudden deaths, especially in three younger patients, was noted,” Roche said, adding that the temporary suspension would allow “a full safety assessment.”

Those seven deaths compare to four deaths in another arm of the study that combined Avastin with a different chemotherapy called FOLFOX.

About 2,000 of the 3,450 patients planned for the test already receiving one of three combinations of Avastin and the chemotherapy regimens will continue to receive their drugs. The rest of the volunteers won’t be enrolled for at least 60 days while the companies try to find what caused the deaths.

The test is designed to see if Avastin can safely be used to prevent colon cancer from recurring in patients in remission. The Food and Drug Administration approved Avastin for patients with advanced colon cancer in 2004 and the drug accounted for $1.1 billion in sales for Genentech last year. Basel, Switzerland-based Roche owns sales rights in Europe, where it was approved last year.
Full story online:
http://www.miami.com/mld/miamiherald/13867271.htm

Comment (0)
• • •

BPH Therapy trial suspended

category: Prostate Cancer posted by admin @ 10:10 pm

QLT says therapy fails Phase II trial

Canada’s QLT, a Vancouver-based developer of light-activated pharmaceuticals, says that it is suspending work on an experimental therapy for
enlarged prostate because the drug “did not meet the study’s primary efficacy objective at three months.”

Researchers announced that lemuteporfin failed to significantly decrease
symptoms of benign prostatic hyperplasia after three months of treatment
compared with a placebo.

“While the decrease in AUA (American Urological Association) Symptom Score was consistent with that seen after other minimally invasive therapies there was no significant difference between treatment and sham-control groups.”

“The preliminary result of this trial does not support initiation of Phase
III clinical trials of lemuteporfin in BPH at this time,” commented Bob
Butchofsky, QLT’s acting chief executive officer. “We intend to complete the
analysis of the data, including the six-month measurements, in order to
determine the best path forward.”

source: QLT’s press release, February 14, 2006.

Comment (0)
• • •

February 12, 2006

Aspartame Questioned

category: Nutrition, Cancer posted by admin @ 12:49 pm

The Lowdown on Sweet?
February 12, 2006
By MELANIE WARNER

note — This New York Times article was published today, Feb 12, in the business section, not in the health section. I have edited the links so that you can get hold of Dr. Soffritti’s full text article in .pdf

WHEN Dr. Morando Soffritti, a cancer researcher in Bologna, Italy, saw the results of his team’s seven-year study on aspartame, he knew he was about to be injected into a bitter controversy over this sweetener, one of the most contentiously debated substances ever added to foods and beverages.

Aspartame is sold under the brand names Nutra-Sweet and Equal and is found in such popular products as Diet Coke, Diet Pepsi, Diet Snapple and Sugar Free Kool-Aid. Hundreds of millions of people consume it worldwide. And Dr. Soffritti’s study concluded that aspartame may cause the dreaded “c” word: cancer.

The research found that the sweetener was associated with unusually high rates of lymphomas, leukemias and other cancers in rats that had been given doses of it starting at what would be equivalent to four to five 20-ounce bottles of diet soda a day for a 150-pound person. The study, which involved 1,900 laboratory rats and cost $1 million, was conducted at the European Ramazzini Foundation of Oncology and Environmental Sciences, a nonprofit organization that studies cancer-causing substances; Dr. Soffritti is its scientific director.

The findings, first released last July, prompted a flurry of criticism from the Calorie Control Council, a trade group for makers of artificial sweeteners that has spent the last 25 years trying to quell fears about aspartame. It said Dr. Soffritti’s study flew in the face of four earlier cancer studies that aspartame’s creator, G. D. Searle & Company, had underwritten and used to persuade the Food and Drug Administration to approve it for human consumption. “Aspartame has been safely consumed for more than a quarter of a century and is one of the most thoroughly studied food additives,” read one news release from the council.
(full story…)

Comment (0)
• • •

February 11, 2006

Omega-6 fatty acids hasten growth of prostate cancer cells

category: Prostate Cancer, Nutrition, COX-2 inhibitors, Cancer posted by admin @ 6:50 pm

2006-02-10 10:16:19 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Adding arachidonic acid, an omega-6 fatty acid, to culture media causes prostate cancer cells to grow twice as fast as usual, according to a report in the February 1st issue of Cancer Research.

“Investigating the reasons for this rapid growth, we discovered that the omega-6 was turning on a dozen inflammatory genes that are known to be important in cancer,” lead author Dr. Millie Hughes-Fulford, from the San Francisco VA Medical Center, said in a statement.

Further analysis indicated that arachidonic acid was activating these genes through a PI3-kinase pathway known to play a key role in the pathogenesis of cancer.

Adding an NSAID or a PI3-kinase inhibitor to the culture media blocked the arachidonic acid-induced proliferation of prostate cancer cells, the findings indicate.

In light of the current findings, Dr. Hughes-Fulford said she now avoids cooking with corn oil, which is known to be high in omega-6 fatty acids. “I’m not a physician, and do not tell people how to eat, but I can tell you what I do in my own home. I use only canola oil and olive oil.”

Cancer Research, Feb 1, 2006.
Arachidonic Acid Activates Phosphatidylinositol 3-Kinase Signaling and Induces Gene Expression in Prostate Cancer
Millie Hughes-Fulford1,2,3, Chai-Fei Li, Jim Boonyaratanakornkit and Sina Sayyah
Department of Veterans Affairs Medical Center; Northern California Institute for Research and Education; and University of California, San Francisco, California

News Source: Reuters Health

Comment (1)
• • •

February 10, 2006

Beyond Headlines - diet and cancer

category: Prostate Cancer, Nutrition posted by admin @ 9:48 pm

Responding to news reports of a large US study published in JAMA, which showed that women who began eating a lower-fat diet at over age 50 were not significantly protected from cancer and heart disease, Sarah Keating M.D., a Canadian doctor, wrote to the Toronto Star to say these women’s diets were not strict enough:

The latest study on low-fat diets is further indication that only truly significant changes to our eating habits can reduce our risk of disease.

As a physician, I know that eliminating meat and other animal products from the diet — a step the low-fat dieters in this study did not take — is proven to reduce the risk of heart disease, obesity, and some forms of cancer.

The China Healthy study and other research on populations around the world have already shown that people on plant-based diets have strikingly low cancer rates. This is because vegetarians typically eat less saturated fat, more fibre and are, on average, slimmer than meat eaters. A 2003 study showed that a vegetarian diet lowers serum cholesterol concentrations about as effectively as cholesterol-lowering statin drugs, a key to preventing heart disease.

By choosing a meatless diet rich in naturally low-fat foods, such as beans, whole grains, fruits, and vegetables, we can significantly reduce our intake of artery-clogging saturated fat and protect ourselves from a number of chronic illnesses.

Toronto Star, Letters, Feb 10, 2006

Although headlines claim that the study has shown no benefit for women on the lower-fat diet, comments from some of the researchers themselves indicate that despite the size and cost of this study, the results are far from definitive.

Why? The women switched to a low fat diet relatively late in life. At 8 years out, the study has not run long enough. By today’s standards, the women received inadequate guidance on types of fat to avoid (especially, they were not advised to avoid trans fats). And many of the women on the supposedly “low-fat” diet drifted away from the relatively moderate target levels of fat back to close to a normal US diet. Even so,the women on the low-fat diet actually did develop less cancer. As reported by The Baltimore Sun,

[The study recruited] 48,835 healthy women with an average age of 62 were enrolled. Forty percent of them were given what is descriobed as intensive counseling to help them reduce their fat intake, while the remainder continued with their normal diet.

Even with the counseling, most women were not able to reduce fat consumption from the average of 35 percent of their calories at the beginning of the study to the target of 20 percent.

At the end of the first year, their fat consumption was 24 percent of calories; by the sixth year it had inched back up to 29 percent.

That lower adherence to the diet than planned was, in part, “why we don’t have definitive results yet,” said biostatistician Ross Prentice of the Fred Hutchinson Cancer Research Center in Seattle.

The study did not differentiate between different types of fat.

Prentice cautioned that the subjects were all “very healthy women who were already following most of the [government’s] dietary guidelines,” so their ability to decrease risk by lowering fat might have been low.

“Unhealthy women may gain more benefit.”

The Mercury News presents a Q&A with one of the study leaders, Marcia Stefanick of Women’s Health Initiative:

Best bet: Eat more fruits, veggies

Q What did the Women’s Health Initiative diet study find?

A The study of 48,835 women found that a low-fat diet alone does not prevent breast cancer, colorectal cancer or heart disease in women over 50. However, there were some signs that a low-fat diet might improve health.

Q What were those signs?

A Women who dramatically lowered the amount of fat they ate and increased their consumption of fruits and vegetables had lower rates of breast cancer than women in a comparison group who did not change their diets. Fewer polyps, a potential sign of colon cancer, were found in women who ate a low-fat diet. Women who ate less saturated fat or trans fats and more fruits and vegetables appeared to have a lower risk of cardiovascular disease.

Q Does this mean that I should abandon my low-fat diet?

A Not necessarily. The women in the low-fat group did not reduce their fat intake as much as researchers had hoped. As a result, they say more study of a truly low-fat diet is needed to determine whether it can prevent cancer. More benefits of a low-fat diet may emerge as the women are studied for another five years. In addition, reducing saturated fat and trans fats have been shown to help improve heart health.

Q If a low-fat diet isn’t going to help, what else can I do to prevent heart disease and cancer?

A Researcher Marcia Stefanick of Stanford University recommends following a diet that’s low in saturated and trans fats, and rich in vegetables and fiber, rather than a generic “low-fat'’ diet. Pay attention to total calories and strive to get your weight to a healthy level. Exercise regularly. Women should also get routine mammograms and screenings for colorectal cancer and heart disease risk. Routinely check your cholesterol profile, blood pressure, blood sugar and body weight.

Comment (0)
• • •

Top Abstracts

category: Prostate Cancer posted by admin @ 5:15 pm

What your doctor may be reading according to Doctors Guide listing of top abstracts in prostate cancer for past 14 days:

1. Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer. Cabrespine A, et al. Urology. 2006 Feb

2. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? Michels J, et al.
Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.

3. Gynecomastia in patients with prostate cancer: update on treatment options.
Autorino R, et al. 1Clinica Urologica, Seconda Universita degli Studi, Napoli, Italy.

4. Insulin Sensitivity During Combined Androgen Blockade for Prostate Cancer.
Smith MR, J Clin Endocrinol Metab. 2006 Jan 24. Massachusetts General Hospital, Boston, MA.
Free Full text in .pdf

5. Prospective comprehensive assessment of sexual function after retropubic non nerve sparing radical prostatectomy for localized prostate cancer. Trinchieri A,et al. Urology Unit Ospedale A. Manzoni Lecco, Italy. Arch Ital Urol Androl. 2005 Dec. “CONCLUSION: Severe erectile dysfunction was observed in most patients after retropubic radical non nerve sparing prostatectomy, but 50% of candidates for radical treatment presents with abnormal erectile function before surgery when appropriately studied. Patients who will recover erectile function could be identified by NPT test before surgery. Depression associated with the fear for intervention is related with erectile dysfunction measured by IIEF scores before surgery, but depression index scores improve after surgery showing that the role of depression in the maintenance of erectile dysfunction is marginal. Sexual counselling and oral treatment facilitate recovery after surgery in patients with optimal erectile function before treatment.”

For 3 month ratings see Doctors Guide Top Abstracts

Comment (0)
• • •

Prostate cancer hormone therapy hard on the heart

category: Prostate Cancer posted by admin @ 11:26 am

Reported by Reuters, Feb 9, We add the abstract from the article, below this report

By Megan Rauscher

NEW YORK (Reuters Health) - Men with recurrent or advanced prostate cancer may be put on hormone therapy to block testosterone production in an effort to halt or slow the growth of the tumor. However, new research shows, this may put them at increased risk for developing insulin resistance and elevated blood sugar levels, which can affect heart health.

These complications of what doctors call androgen-deprivation therapy or ADT may contribute to the high rate of heart disease in men with prostate cancer, Baltimore-based investigators report in the journal Cancer.
(full story…)

Comment (0)
• • •
« Previous Page — Next Page »
PSA Rising: http://www.psa-rising.com